JUN 08, 2016 4:35 AM PDT

Childhood Blood Cancer Has Two New Culprits

WRITTEN BY: Xuan Pham
Researchers at Lund University in Sweden recently announced the discovery of two new types of childhood blood cancers. The discovery was made possible by the next generation sequencing (NGS) platform, which has revolutionized the medical and diagnostic field even in the past few years. With this discovery, the team hopes to enable more personalized treatment and overall outcome of these childhood cancers.

cancer.osu.eduThough considered a rare disease, acute lymphoblastic leukemia (ALL) is the most common form of childhood cancer, peaking in early childhood between the ages of 2 and 4. The cancer involves the overproduction of immature white blood cells in the bone marrow. These cancerous cells invade the blood and other organ systems, causing massive cell death and damage in a short amount of time.

Fortunately, doctors have an arsenal of weapons that are effective against ALL. These include radiation therapy, bone marrow transplantation, and chemotherapy agents like methotrexate, vincristine, and cytarabine. Targeted drugs like Gleevec are also effective against ALL, and have the benefit of less side-effects than traditional chemotherapy. With treatment, the 5-year survival rate for the majority of ALL patients is 70 percent. However, treatments and outcome vary depending on the ALL type. Thus, knowing the possible subtypes of ALL is highly informative for doctors and patients.

"Like all types of cancer, childhood leukemia is caused by genetic mutations in normal cells, which are then transformed into cancer cells. Finding the critical mutations in the diseased cells is an important condition for understanding the mechanisms of the disease and ultimately discovering new therapies," said Thoas Fioretos, professor and senior consultant at the Division of Clinical Genetics, and senior study author.

In sequencing leukemia cells from 283 children, Fioretos’ team uncovered two new genetic mutations that cause the childhood cancer. "One type occurs when a gene called DUX4, which is normally inactive in blood cells, becomes activated when the gene is relocated in the genome. The second type resembles a previously known type of childhood leukemia, but is caused by other genetic mutations," said Henrik Lilljebjörn, first author of the study. Per their report in Nature Communications, the second mutation involves the ETV6 and RUNX1 genes.

"Over the last few years, our research group has worked extremely intensely on this study, which would not have been possible without collaboration with several other researchers at Lund University, Skåne University Hospital, and research groups in Germany," said Fioretos, who recently presented a webinar for LabRoots.

So far scientists know of six major types of childhood ALL. The new study adds significantly to what’s known, which will hopefully lead to better diagnosis and treatment of the disease in children.
 


Additional source: Science Daily
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 07, 2020
Cancer
Identifying Robust Tumor Features for Better Radiomics
SEP 07, 2020
Identifying Robust Tumor Features for Better Radiomics
With the advancement of technology comes the renovation of classical medical techniques. Diagnostic is one of the areas ...
OCT 14, 2020
Cancer
Research suggests statins could reduce the risk of cancer
OCT 14, 2020
Research suggests statins could reduce the risk of cancer
New research published in the journal eLife provides evidence that statins, the common cholesterol-lowering drugs, could ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 13, 2020
Cancer
Predictive model assesses risk of adverse side effects for chemotherapy patients
NOV 13, 2020
Predictive model assesses risk of adverse side effects for chemotherapy patients
New research published in npj Systems Biology and Applications showcases a model capable of predicting which patien ...
NOV 21, 2020
Cancer
Hospital patients want processed meats removed from hospital menus
NOV 21, 2020
Hospital patients want processed meats removed from hospital menus
A survey published in the Journal of Hospital Management and Health Policy reports that most patients are in agreem ...
Loading Comments...